Anti-thymocyte serum delays clearance of poliovirus from the mouse central nervous system

Antibody is of primary importance for protection from poliovirus-induced paralysis (poliomyelitis) and from other enterovirus infections. However, the components of the immune response involved in the clearance of an established enterovirus infection of the central nervous system (CNS) are not known. To assess the effect of thymus-dependent immune functions on a CNS poliovirus infection, adult BALB/c mice inoculated intracerebrally with the W-2 strain of human poliovirus type 2 (PV2) were treated with anti-thymocyte serum (ATS) and analyzed for clinical disease, virus persistence, antibody responses, and T-cell proliferation (Tprlf). Half (22 of 44) of the ATS-treated mice showed paralysis and death as compared to 27% (17 of 62) of control mice treated with normal rabbit serum. Virus persisted in the brain for 45 days after infection in 43% (13 of 30) of ATS-treated mice as compared to 3% (1 of 30) of controls. Tprlf to PV as well as Tprlf and antibody responses to control antigens were markedly reduced in ATS-treated mice. However, antibody responses to PV in ATS-treated mice were not suppressed, suggesting that PV may be a T-cell-independent antigen. These findings indicate that ATS-suppressible functions contribute to the clearance of PV from the mouse CNS, apparently via a sensitized T-cell mechanism.